Cargando…

Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes

BACKGROUND: Anakinra pharmacokinetics and pharmacodynamics were investigated in children and adolescents treated for systemic-onset juvenile idiopathic arthritis (SJIA) and autoinflammatory syndromes. METHODS: Anakinra was given subcutaneously at doses between 2 and 10 mg/kg (maximum 100 mg) per day...

Descripción completa

Detalles Bibliográficos
Autores principales:	Urien, Saik, Bardin, Christophe, Bader-Meunier, Brigitte, Mouy, Richard, Compeyrot-Lacassagne, Sandrine, Foissac, Franz, Florkin, Benoît, Wouters, Carine, Neven, Bénédicte, Treluyer, Jean-Marc, Quartier, Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750485/ https://www.ncbi.nlm.nih.gov/pubmed/23915458 http://dx.doi.org/10.1186/2050-6511-14-40

Ejemplares similares

Diversity in clinical manifestations of autoinflammatory syndromes
por: Boiu, S, et al.
Publicado: (2011)

P03-018 - Diversity in presenting manifestations of AUTOINFL
por: Boiu, S, et al.
Publicado: (2013)

PReS-FINAL-2111: Cytomegalovirus, Epstein Barr virus and Varicella-Zoster virus infections in children with juvenile idiopathic arthritis treated with biologics
por: Remy Piccolo, V, et al.
Publicado: (2013)

Clinical features of children with enthesitis-related juvenile idiopathic arthritis / juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre
por: Goirand, Maxime, et al.
Publicado: (2018)

PReS-FINAL-2133: Drug survival and switching of biological agents in systemic juvenile idiopathic arthritis
por: Woerner, A, et al.
Publicado: (2013)

Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent
por: Woerner, A, et al.
Publicado: (2015)

Cerebral autoinflammatory disease treated with anakinra
por: Jang, Yoonhyuk, et al.
Publicado: (2018)

The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Quartier, Pierre, et al.
Publicado: (2018)

PW03-033 - SLC29A3 mutation: a new autoinflammatory condition
por: Melki, I, et al.
Publicado: (2013)

Sustained remission after haploidentical bone marrow transplantation in a child with refractory systemic juvenile idiopathic arthritis
por: Morelle, Guillaume, et al.
Publicado: (2021)

Anakinra treatment for refractory cerebral autoinflammatory responses
por: Jang, Yoonhyuk, et al.
Publicado: (2022)

The off-label use of anakinra in pediatric systemic autoinflammatory diseases
por: Maniscalco, Valerio, et al.
Publicado: (2020)

PW02-016 - 41 cases of TRAPS, a rare autoinflammatory disease
por: Chastang, M-C, et al.
Publicado: (2013)

Efficacy, safety and effect on gene expression profiling of anakinra in systemic-onset juvenile idiopathic arthritis: final results of a randomised, double-blind, placebo-controlled trial (ANAJIS)
por: Quartier, P, et al.
Publicado: (2008)

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
por: Quartier, Pierre, et al.
Publicado: (2010)

Natural Killer Cells in Systemic Autoinflammatory Diseases: A Focus on Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome
por: Vandenhaute, Jessica, et al.
Publicado: (2020)

Dry synovitis, a rare entity distinct from juvenile idiopathic arthritis
por: De Somer, Lien, et al.
Publicado: (2023)

Mullins’ syndrome: a new gammopathy-related autoinflammatory syndrome resistant to anakinra
por: Longhurst, H.J., et al.
Publicado: (2015)

Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra
por: Terrada, Celine, et al.
Publicado: (2011)

Efficacy and safety of anakinra for undifferentiated autoinflammatory diseases in children: a retrospective case review
por: Garg, Suchika, et al.
Publicado: (2019)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
por: Ruperto, N, et al.
Publicado: (2008)

A novel mutation in NLRC4 in a large pedigree with an anakinra responsive autoinflammatory disease
por: Volker-Touw, N, et al.
Publicado: (2015)

Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined genetic cause
por: Harrison, S, et al.
Publicado: (2015)

Pediatric uveitis: Role of the pediatrician
por: Shivpuri, Abhay, et al.
Publicado: (2022)

Creation of a cohort of French patients with chronic recurrent multifocal osteitis : preliminary results
por: Wipff, J, et al.
Publicado: (2011)

Safety of rituximab in children with auto-immune diseases
por: Bader-Meunier, B, et al.
Publicado: (2008)

Juvenile overlap myositis: retrospective study about 20 cases
por: Piccolo, Vanessa Remy, et al.
Publicado: (2014)

Targeting the chemokine receptor CXCR4 with histamine analog to reduce inflammation in juvenile arthritis
por: Bekaddour, Nassima, et al.
Publicado: (2023)

Evaluation of Hydroxychloroquine Blood Concentrations and Effects in Childhood-Onset Systemic Lupus Erythematosus
por: Zahr, Noël, et al.
Publicado: (2021)

Anakinra in children and adults with Still’s disease
por: Vastert, Sebastiaan J, et al.
Publicado: (2019)

Systemic-onset juvenile rheumatoid arthritis and ANCA-associated glomerulonephritis
por: Belot, A, et al.
Publicado: (2008)

Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome
por: Quartier, Pierre
Publicado: (2011)

Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis
por: Day, T G, et al.
Publicado: (2008)

Curation and expansion of the Human Phenotype Ontology for systemic autoinflammatory diseases improves phenotype-driven disease-matching
por: Maassen, Willem, et al.
Publicado: (2023)

Pharmacokinetics, hemodynamic and metabolic effects of epinephrine to prevent post-operative low cardiac output syndrome in children
por: Oualha, Mehdi, et al.
Publicado: (2014)

Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist
por: Papadopoulou, Charalampia, et al.
Publicado: (2020)

Mevalonate kinase deficiency (MKD): long-term follow-up of clinical and biological features in 40 patients
por: Florkin, B, et al.
Publicado: (2008)

Clinical characteristics, management and outcomes in patients with juvenile dermatomyositis requiring admission in pediatric intensive care unit
por: Besancon, Alix, et al.
Publicado: (2014)

Chronic and recurrent non-infectious paediatric-onset uveitis: a French cohort
por: Morelle, Guillaume, et al.
Publicado: (2019)

Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
por: Bouazza, Naïm, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_rbk2bbhibbqbtejb4gui6ndksk